| ID | 1141 |
| Name of the vaccine | Prevnar |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks and older |
| Description of the vaccine | Pneumococcal 7-valent conjugate vaccine (PCV 7) [Diphtheria CRM197 Protein]. |
| Name of the manufacturer | Wyeth Pharmaceuticals Inc. |
| Name of the manufacturing country | Philadelphia |
| Year of manufacture | 2000 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | 88.9% efficacy in intent-to-treat analysis for all pneumococcal serotypes (between 1995-1998). |
| Vaccine formulation | Homogeneous, white suspension. |
| Dosage | 0.5 ml dose.
For infants : three doses and fourth dose at 12-15 months, dosing interval is 4 to 8 weeks.
Previously unvaccinated children 7 months or older :
7-11 months of age - 3 doses
12-23 months of age - 2 doses
Greater than or equal to 24 months to 9 years - 1 dose |
| Mechanism of action | Induces functional antibodies to all vaccine serotypes. |
| Route of administration | Intramuscular |
| Indications | Prevents invasive disease caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F and 23F). Also indicated for protection against otitis media. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For otitis media also. |
| Side effects of vaccine | Injection site dermatitis, urticaria and pruritus, lymphadenopathy localized to injection site, hypersensitivity reaction, crying, angioneurotic edema, erythema multiforme. |
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/76076/download |
| Other name | NA |
| Additional Links | NA
|